1-3 of 3
David Loury, PhD
Close
Sort by
Journal Articles

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Nathan Fowler, MD, Jeff Porte Sharman, MD, Sonali M Smith, MD, Thomas Boyd, MD, Barbara Grant, MD, Kathryn S. Kolibaba, MD, Richard R. Furman, MD, Joseph Buggy, David Loury, PhD, Ahmed Hamdy, Ranjana Advani, MD
Journal: Blood
Blood (2010) 116 (21): 964.
https://doi.org/10.1182/blood.V116.21.964.964
Published: 2010
Journal Articles

The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies

Jan A. Burger, MD, PhD, Susan O'Brien, Nathan Fowler, MD, Ranjana Advani, MD, Jeff Porte Sharman, MD, Richard R. Furman, MD, Raquel Izumi, PhD, Joseph Buggy, PhD, David Loury, PhD, Ahmed Hamdy, MD, John C. Byrd, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2010) 116 (21): 57.
https://doi.org/10.1182/blood.V116.21.57.57
Published: 2010
Journal Articles

Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.

Andrew M Evens, DO, MSc, Weiyun Ai, MD, PhD, Sriram Balasubramanian, PhD, Mint Sirisawad, M.S., Chitra Mani, PhD, Martha Guerra, RN, Nancy Szakacs, BS, MBA, David Loury, PhD, Joseph J Buggy, Ph.D., Ahmed Hamdy, MD, Julie M. Vose, M.D., Nancy L Bartlett, MD
Journal: Blood
Blood (2009) 114 (22): 2726.
https://doi.org/10.1182/blood.V114.22.2726.2726
Published: 2009